Recent publications.
  • Ukkola I, Nummela P, Kero M, Tammio H, Tuominen J, Kairisto V, Kallajoki M, Haglund C, Peltomäki P, Kytölä S, Ristimäki A. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers. Virchows Arch. doi: 10.1007/s00428-022-03302-x, 2022.
  • Ukkola I, Nummela P, Pasanen A, Kero M, Lepistö A, Kytölä S, Bützow R, Ristimäki A. Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer. Virchows Arch. 479: 471-9, 2021.
  • Holm M, Andersson E, Osterlund E, Ovissi A, Soveri LM, Anttonen AK, Kytölä S, Aittomäki K, Österlund P, Ristimäki A. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing. PlosOne. 15:e0239819, 2020.
  • Nummela P, Heiskanen A, Kytölä S, Haglund C, Lepistö A, Satomaa T, Ristimäki A. Altered linkage pattern of N-glycan sialic acids in pseudomyxoma peritonei. Glycobiology. 31:211-222, 2021.
  • Holm M, Nummela P, Heiskanen A, Satomaa T, Kaprio T, Mustonen H, Ristimäki A, Haglund C. N-glycomic profiling of colorectal cancer according to tumor stage and location. PloS One. 15:e0234989, 2020.
  • Holm M, Joenväärä S, Saraswat M, Tohmola T, Ristimäki A, Renkonen R, Haglund C. Plasma protein expression differs between colorectal cancer patients depending on primary tumor location. Cancer Med. 9:5221-5234, 2020.
  • Holm M, Joenväärä S, Saraswat M, Tohmola T, Ristimäki A, Renkonen R, Haglund C. Preoperative radiotherapy leads to significant differences in the plasma protein profile of rectal cancer patients. Oncology. 98: 493-500, 2020.
  • Holm M, Joenväärä S, Saraswat M, Mustonen H, Tohmola T, Ristimäki A, Renkonen R, Haglund C. Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome. FASEB Bioadv. 1:723-730, 2019.
  • Holm M, Saraswat M, Joenväärä S, Ristimäki A, Haglund C, Renkonen R. Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. PLoS One. 13:e0195354, 2018.
  • Saarinen L, Nummela P, Leinonen H, Heiskanen A, Thiel A, Haglund C, Lepistö A, Satomaa T, Hautaniemi S, Ristimäki A. Glycomic profiling highlights increased fucosylation in pseudomyxoma peritonei. Mol Cell Proteomics. 17:2107-18 , 2018.
  • Saarinen L, Nummela P, Thiel A, Lehtonen R, Järvinen P, Järvinen H, Aaltonen LA, Lepistö A, Hautaniemi S, Ristimäki A. Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei. PLoS One. 12:e0174898, 2017.
  • Nummela P, Leinonen H, Järvinen P, Thiel A, Järvinen H, Lepistö A, Ristimäki A. Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei. Hum Pathol. 54:47-54, 2016.
  • Nummela P, Saarinen L, Thiel A, Järvinen P, Lehtonen R, Lepistö A, Järvinen H, Aaltonen LA, Hautaniemi S, Ristimäki A. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int J Cancer. 136:E282-9, 2015.
  • Thiel A, Moza M, Kytölä S, Orpana A, Jahkola T, Hernberg M, Virolainen S, Ristimäki A. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. Hum Pathol. 46:169-75, 2015.
  • Thiel A, Heinonen M, Kantonen J, Gylling A, Lahtinen L, Korhonen M, Kytölä S, Mecklin JP, Orpana A, Peltomäki P, Ristimäki A. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch. 463:613-21, 2013.
  • Thiel A, Narko K, Heinonen MM, Hemmes A, Tomasetto C, Rio M, Haglund C, Mäkelä T, Ristimäki A. Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int J Cancer. 131:1032-41, 2012.